Clinical Trial Update: A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating UB-221 IV as add-on therapy for chronic spontaneous urticaria, focusing on pharmacodynamics, pharmacokinetics, safety, and eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• UB-221

Snippet

Sponsor: United BioPharma | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: UNKNOWN